SCHEMBL20551920

SCHEMBL20551920

OCC1(OCc2ccccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
IDO1 P14902 1/20 0.40
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
SLC1A1 P43005 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
KMT2A Q03164 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
AGXT P21549 1/20 0.39
ALDH1A1 P00352 3/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A3 Q01959 2/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9020639 0.92 TSHR (0.40) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL31721379 0.87 GRIN1 (0.36) TSHRCYP2C19KMT2AOPRM1OPRD1
SCHEMBL20552640 0.83 SLC1A3 (0.40) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL15130271 0.83 TSHR (0.39) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL31114231 0.80 TSHR (0.43) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL23275795 0.77 CA2 (0.41) TSHRSLC1A3SLC1A2SLC1A1CYP1A2
SCHEMBL12981785 0.74 NR5A2 (0.41) TSHROPRM1OPRD1OPRK1OPRL1
SCHEMBL19094203 0.73 TSHR (0.40) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL8566404 0.73 TSHR (0.40) TSHRIDO1SLC1A3SLC1A2SLC1A1
SCHEMBL31114220 0.73 ALDH1A1 (0.45) SLC1A3SLC1A2SLC1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-12527763-B2 Pyrrole amide compound and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-01-20 US disclosed
WO-2024254539-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
CN-118684666-A KIF18A inhibitors and uses thereof 诺沃斯达药业(上海)有限公司 2024-09-24 CN disclosed
WO-2023083191-A1 BENZODIAZEPINE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 四川大学华西医院 2023-05-19 WO disclosed
US-20220211665-A1 PYRROLE AMIDE COMPOUND AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-07-07 US disclosed
CN-114702427-A Pyrrole amide compound and application thereof 年衍药业(珠海)有限公司 2022-07-05 CN disclosed
CN-112707854-B Pyrrole amide compound and application thereof 年衍药业(珠海)有限公司 2022-03-15 CN disclosed
EP-3950674-A1 PYRROLE AMIDE COMPOUND AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-02-09 EP disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
WO-2021078135-A1 PYRROLE AMIDE COMPOUND AND USE THEREOF 广东东阳光药业有限公司 2021-04-29 WO disclosed
CN-112707854-A Pyrrole amide compound and application thereof 广东东阳光药业有限公司 2021-04-27 CN disclosed
CN-111132673-A Non-fused tricyclic compounds 维瓦斯治疗公司 2020-05-08 CN disclosed
EP-3618818-A1 NON-FUSED TRICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-03-11 EP disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 US disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 US disclosed
WO-2018204532-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2018-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS YAP1, MYC, TEAD2 TSHR 2644/4885IDO1 3967/4885SLC1A3 4249/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 TSHR 1291/4885IDO1 599/4885SLC1A3 3048/4885
US-12527763-B2 Pyrrole amide compound and use thereof NR3C2, AVPR2, MC2R TSHR 86/4885IDO1 3323/4885SLC1A3 531/4885
US-11186554-B2 Non-fused tricyclic compounds YAP1, MYC, TEAD2 TSHR 2644/4885IDO1 3967/4885SLC1A3 4249/4885
US-20220211665-A1 PYRROLE AMIDE COMPOUND AND USE THEREOF MC2R, NR3C2, AVPR2 TSHR 97/4885IDO1 3889/4885SLC1A3 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.